Tumor markers

The MUC-1 breast cancer antigen is a mucin-type glycoprotein. It is secreted from tumor cells and can be used as a serological marker of breast cancer.

The CanAg AFP EIA kit is intended for the quantitative determination of α-Fetoprotein (AFP) in human serum.

The CanAg CA15-3 EIA kit is intended for the quantitative determination of the cancer associated antigen MUC-1 (CA15-3) in serum.

The CanAg CA242 EIA kit is intended for the quantitative determination of CA242 cancer antigen in serum.

The CYFRA 21-1 EIA kit is intended for the quantitative determination of soluble cytokeratin 19 fragments in human serum. The assay is to be used as an aid in monitoring disease progression during the course of disease and treatment in lung cancer patients. Serial testing for patient CYFRA 21-1 assay values should be used in conjunction with other clinical methods used for monitoring lung cancer.

The CanAg ProGRP EIA kit is an immunoassay for the quantitative determination of ProGRP in serum. The CanAg ProGRP assay is to be used as an aid in the differential diagnosis and in monitoring disease progression during the course of disease and treatment in small cell lung cancer patients. Testing for patient proGRP assay values should be used in conjunction with other clinical methods used in the management of patients with small cell lung cancer.

The CanAg SCC EIA kit is intended for the quantitative determination of squamous cell carcinoma (SCC) antigen in serum as an aid in the management of patients with squamous cell carcinoma.

The combination of antibodies against hidden epitopes of PSA with antibodies against exposed epitopes may be used for the development of specific assays for detection of Free PSA.

The HE4 EIA is an enzyme immunometric assay for the quantitative determination of HE4 in human serum. The assay is to be used as an aid in monitoring response to therapy for patients with invasive epithelial ovarian cancer. Serial testing for patient HE4 assay values should be used in conjunction with other clinical methods used for monitoring ovarian cancer. It is further intended to be used in conjunction with either ARCHITECT CA 125 II or CanAg CA125 EIA or Lumipulse G CA125II as an aid in estimating the risk of epithelial ovarian cancer in premenopausal and postmenopausal women presenting with pelvic mass. The results must be interpreted in conjunction with other methods in accordance with standard clinical management guidelines.

Immunoreaction cartridges for in vitro diagnostic use with the LUMIPULSE G System for the quantitative measurement of alpha-fetoprotein (AFP) in serum or plasma. The assay utilises proven CLEIA (ChemiLuminescent Enzyme Immunoassay) technology with results that are available in up to 35 minutes.

For in vitro diagnostic use with the LUMIPULSE G System for the quantitative measurement of CA15-3 in serum or plasma.

Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of carcinoembryonic antigen (CEA) in serum or plasma.

Immunoreaction cartridges for for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of free prostate specific antigen (free PSA) in human serum or plasma.

Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative determination Soluble Mesothelin Related Peptides (SMRP) in human serum or plasma.

Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of pepsinogen Ⅱ in specimens based on CLEIA technology by two-step sandwich immunoassay on the LUMIPULSE G system.

Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of Pro-gastrin-releasing peptide [ProGRP (31-98)] in serum or plasma.

Immunoreaction cartridges for in vitro diagnostic use with the LUMIPULSE G instruments for the quantitative measurement of squamous cell carcinoma (SCC) antigen in human serum or plasma samples as an aid in the management of patients with squamous cell carcinoma.

Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of Beta 2-microglobulin (β2-m) in serum or plasma.

Upon request we may also supply the following antibodies targeting cancer-associated antigens.